Ch 21: Renin Inhibitors

Which pharmacologic strategy interrupts the conversion of angiotensin I to angiotensin II?

Which drug binds to the active site of renin, inhibiting the binding of renin to angiotensinogen?

Which drug class are competitive antagonists at the AT1 receptor and inhibit the target-organ effects of angiotensin II?

Which drug class blocks aldosterone action at the nephron collecting duct?

Which drug is the first and currently only approved inhibitor of the enzymatic activity of renin?

With which drug class should Aliskiren not be combined in patients with diabetes or chronic kidney disease of stage 3?

In which patients has Aliskiren been approved for use?

Which of the following is a pharmacologic modulator that acts directly on the nephron segments to alter renal Na+ handling?

Which class of pharmacologic agents prevents the generation of angiotensin I?

Which pharmacologic strategy interrupts the conversion of angiotensin I to angiotensin II?

Which drug class are competitive antagonists at the AT1 receptor and inhibit the target-organ effects of angiotensin II?

What is the primary mechanism of action of Aliskiren?

With which drug class should Aliskiren not be combined in patients with diabetes or chronic kidney disease of stage 3?

In which patients has Aliskiren been approved for use?

Which drug class is considered a competitive antagonist at the AT1 receptor and inhibits the target-organ effects of angiotensin II?

Which pharmacologic strategy prevents the generation of angiotensin I?

Which drug class directly targets renal ion transporter or channel function to increase renal Na+ excretion?

Which pharmacologic modulator acts directly on Na+ reabsorption through mechanisms less well understood than those of the diuretics?